Clinical trial SASCIA
Phase III postneoadjuvant study evaluating Sacituzumab Govitecan, an Antibody Drug Conjugate in primary HER2 - negative breast cancer patients with high relapse risk after standard neoadjuvant treatment
Cancers | |
---|---|
Organ | Breast |
Trial status | Trial closed |
Investigator | |
Trial type |
Interventional with experimental drug
|
Phase | Trial phase 3 |
Academic trial | Non |
Sponsor | IBCSG |
EudraCT Identifier | 2019-004100-35 |
ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT04595565 |
Last update |